🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against superbug strains of the infection, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing around the world, with estimates suggesting over 82 million new cases each year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is additionally indicated for urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a significant shift in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to data released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The research included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have shared hope. The availability of a easy-to-administer therapy such as this is seen as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.